We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
This News Item updates and clarifies the TRAVAX news item on 10 October 2012.
The advice from the MHRA and Sanofi Pasteur MSD is not to revaccinate those travellers who have received vaccine from the affected batches.
Some recipients of vaccine from the affected batches are likely to have attained a normal level of protection and the remainder will have a degree of protection against typhoid. Attention to personal hygiene and food and water safety should be re-enforced.
Healthcare professionals should, however, use their clinical judgement following individual risk assessment as it may be prudent to revaccinate travellers considered to be at particular risk. There is currently a limited supply of injectable typhoid vaccines in the market place but the oral live vaccine is available (Vivotif :Typhoid Vaccine Live Oral Ty21a).
